Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials

por Habr, Dany, McRoy, Lynn, Papadimitrakopoulou, Vassiliki A
Publicado 2021

An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer()

por Haynes, Brian C., Blidner, Richard A., Cardwell, Robyn D., Zeigler, Robert, Gokul, Shobha, Thibert, Julie R., Chen, Liangjing, Fujimoto, Junya, Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio I., Latham, Gary J.
Publicado 2019

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Adv...

por Negrao, Marcelo V., Papadimitrakopoulou, Vassiliki A., Price, Andrew C., Tam, Alda L., Furqan, Muhammad, Laroia, Sandeep T., Massarelli, Erminia, Pacheco, Jose, Heymach, John V., Tsao, Anne S., Walker, Gary V., Vora, Lalit, Mauro, David, Kelley, Heather, Wooldridge, James E., Krieg, Arthur M., Niu, Jiaxin
Publicado 2022

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

por Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Publicado 2021

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400...

por Leighl, Natasha B, Redman, Mary W, Rizvi, Naiyer, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Wade, James L, Irvin, William J, Reddy, Sreekanth C, Crawford, Jeffrey, Bradley, Jeffrey D, Stinchcombe, Thomas E, Ramalingam, Suresh S, Miao, Jieling, Minichiello, Katherine, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A, Kelly, Karen, Gandara, David R
Publicado 2021

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

por Brahmer, Julie R., Govindan, Ramaswamy, Anders, Robert A., Antonia, Scott J., Sagorsky, Sarah, Davies, Marianne J., Dubinett, Steven M., Ferris, Andrea, Gandhi, Leena, Garon, Edward B., Hellmann, Matthew D., Hirsch, Fred R., Malik, Shakuntala, Neal, Joel W., Papadimitrakopoulou, Vassiliki A., Rimm, David L., Schwartz, Lawrence H., Sepesi, Boris, Yeap, Beow Yong, Rizvi, Naiyer A., Herbst, Roy S.
Publicado 2018

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

por Nong, Jingying, Gong, Yuhua, Guan, Yanfang, Yi, Xin, Yi, Yuting, Chang, Lianpeng, Yang, Ling, Lv, Jialin, Guo, Zhirong, Jia, Hongyan, Chu, Yuxing, Liu, Tao, Chen, Ming, Byers, Lauren, Roarty, Emily, Lam, Vincent K., Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio, Heymach, John V., Glisson, Bonnie, Liao, Zhongxing, Lee, J. Jack, Futreal, P. Andrew, Zhang, Shucai, Xia, Xuefeng, Zhang, Jianjun, Wang, Jinghui
Publicado 2018

Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

por Nong, Jingying, Gong, Yuhua, Guan, Yanfang, Yi, Xin, Yi, Yuting, Chang, Lianpeng, Yang, Ling, Lv, Jialin, Guo, Zhirong, Jia, Hongyan, Chu, Yuxing, Liu, Tao, Chen, Ming, Byers, Lauren, Roarty, Emily, Lam, Vincent K., Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio, Heymach, John V., Glisson, Bonnie, Liao, Zhongxing, Lee, J. Jack, Futreal, P. Andrew, Zhang, Shucai, Xia, Xuefeng, Zhang, Jianjun, Wang, Jinghui
Publicado 2019

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

por Hegde, Aparna, Andreev-Drakhlin, Alexander Y, Roszik, Jason, Huang, Le, Liu, Shuang, Hess, Kenneth, Cabanillas, Maria, Hu, Mimi I, Busaidy, Naifa L, Sherman, Steven I, Dadu, Ramona, Grubbs, Elizabeth G, Ali, Siraj M, Lee, Jessica, Elamin, Yasir Y, Simon, George R, Blumenschein, Jr, George R, Papadimitrakopoulou, Vassiliki A, Hong, David, Meric-Bernstam, Funda, Heymach, John, Subbiah, Vivek
Publicado 2020

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

por Kluger, Harriet M., Tawbi, Hussein A., Ascierto, Maria L., Bowden, Michaela, Callahan, Margaret K., Cha, Edward, Chen, Helen X., Drake, Charles G., Feltquate, David M., Ferris, Robert L., Gulley, James L., Gupta, Shilpa, Humphrey, Rachel W., LaVallee, Theresa M., Le, Dung T., Hubbard-Lucey, Vanessa M., Papadimitrakopoulou, Vassiliki A., Postow, Michael A., Rubin, Eric H., Sharon, Elad, Taube, Janis M., Topalian, Suzanne L., Zappasodi, Roberta, Sznol, Mario, Sullivan, Ryan J.
Publicado 2020